Aardvark Therapeutics Inc
AARDHealthcare·Biotechnology·USA·Nano·NASD·Nov 12 • 3:59 PM ET
1.52-0.07 (-4.40%)
2026-11-13 12:40 CET
Market cap
$33.26M
Revenue, TTM
0.00 USD m
Net income, TTM
-69.89 USD m
Free cash flow, TTM
-69.41 USD m
EPS diluted, TTM
-3.21
Price
AARD against its 20, 50 and 200-day averagesPatternshover a marker to name it
90.8% under the 52-week high of 16.60 on 22 Jan 2026. 52-week low 0.93 on 26 Oct 2026. Last 15 sessions, 222.6% high to low
Volume 0.00× normal · the session has not printed · the line is the 50-bar volume average
Setup. RS line 0
CANSLIM 1 of 6 — fails: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); 52-Week High/Low: 0-10% below High; Performance: Year +50%; Institutional Ownership: Over 50%
VCP 3 of 6 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High
Minervini 0 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High; Performance: Year +50%
Zanger 1 of 5 — fails: RSI (14): Not Oversold (>50); 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5; 200-Day Simple Moving Average: Price above SMA200
Leaders 1 of 5 — fails: 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%; 52-Week High/Low: 0-10% below High
Breakout 0 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2; 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200
Growth 0 of 4 — fails: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); EPS Growth Next Year: High (>25%); Return on Equity: Over +15%
Quality 2 of 5 — fails: Return on Equity: Over +15% — not on the tape: Net Profit Margin: High (>20%); P/E: Under 25
Value 2 of 4 — fails: Return on Equity: Over +15% — not on the tape: P/E: Under 15
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 2 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%
Accumulation 0 of 4 — fails: Institutional Ownership: Over 30%; Institutional Transactions: Over +10%; 200-Day Simple Moving Average: Price above SMA200; Performance: Year Up
Relative Strength 1 of 3 — fails: Performance: Year +100%; 200-Day Simple Moving Average: Price above SMA200
Profile
AARD52-week range, 4% of the way up
0.9316.60
Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel, small-molecule therapeutics for the treatment of metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.
| Employees | 40 |
|---|---|
| IPO | Feb 13, 2025 |
| Beta | 4.30 |
| ATR, 14d | 0.36 |
| Rel volume | 0.00 |
| Short float | 8.10% |
| Insider own | 41.42% |
| Inst own | 25.05% |
Snapshot
6 groupsValuation
| Index | - |
|---|---|
| Market Cap | $33.26M |
| Enterprise Value | -39.93M |
| Income | -69.89M |
| Sales | 0.00M |
| Book / share | 3.42 |
| Cash / share | 3.38 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 40 |
| IPO | Feb 13, 2025 |
Ratios
| Price / earnings | - |
|---|---|
| Forward price / earnings | - |
| Price / earnings / growth | - |
| Price / sales | - |
| Price / book | 0.44 |
| Price / cash | 0.45 |
| Price / free cash flow | - |
| Value / cash profit | - |
| Value / sales | - |
| Quick Ratio | 12.63 |
| Current Ratio | 12.63 |
| Debt / equity | 0.01 |
| Long-term debt / equity | 0.00 |
| Options and short | Yes / No |
Earnings
| Earnings / share | -3.21 |
|---|---|
| Earnings next year | -2.36 |
| Earnings next quarter | -0.72 |
| Earnings this year | -5.15% |
| Earnings next year | 23.46% |
| Earnings growth, 5 years | 8.96% |
| Past earnings growth | -60.85% - |
| Past sales growth | - - |
| Earnings vs last year | -89.45% |
| Sales vs last year | - |
| Earnings vs last quarter | 0.56% |
| Sales vs last quarter | - |
| Earnings | Nov 12 |
| Surprise | 24.52% - |
Ownership
| Insiders own | 41.42% |
|---|---|
| Insider trades | -0.84% |
| Institutions own | 25.05% |
| Institution trades | -6.84% |
| Return on assets | -61.06% |
| Return on equity | -66.02% |
| Return on capital | -93.09% |
| Gross Margin | - |
| Operating margin | - |
| Profit Margin | - |
| 20-day average | -23.35% |
| 50-day average | -60.49% |
| 200-day average | -73.36% |
Technical
| Shares out | 21.88M |
|---|---|
| Shares floating | 12.82M |
| Short / float | 8.10% |
| Short ratio | 1.69 |
| Short interest | 1.04M |
| 52-week high | 16.60 -90.8% |
| 52-week low | 0.93 +63.4% |
| Volatility | 14.70% 20.50% |
| Average range | 0.36 |
| Strength index | 33.74 |
| Market sensitivity | 4.30 |
| Relative volume | 0.00 |
| Avg Volume | 614.02K |
| Volume | 0 |
Performance
| Perf Week | 36.94% |
|---|---|
| Perf Month | -60.82% |
| Perf Quarter | -76.76% |
| Perf Half Y | -77.41% |
| Perf YTD | -88.42% |
| Perf Year | -85.83% |
| Perf 3Y | - |
| Perf 5Y | - |
| Perf 10Y | - |
| Recommendation | 2.55 |
| Target Price | 4.57 |
| Prev Close | 1.52 |
| Price | 1.52 |
| Change % | 0.00% |
Analyst ratings
latest 10 of 17| Date | Action | Analyst | Rating change | Target | Implied |
|---|---|---|---|---|---|
| Nov 05, 2026 | Downgrade | Raymond James | Strong Buy → Mkt Perform | ||
| May 15, 2026 | Downgrade | Morgan Stanley | Equal-Weight → Underweight | $3 | +97.4% |
| Mar 02, 2026 | Downgrade | Stifel | Buy → Hold | $6 | +294.7% |
| Mar 02, 2026 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform | $6 | +294.7% |
| Mar 02, 2026 | Downgrade | Morgan Stanley | Overweight → Equal-Weight | $7 | +360.5% |
| Mar 02, 2026 | Downgrade | H.C. Wainwright | Buy → Neutral | ||
| Jan 28, 2026 | Initiated | B. Riley Securities | Buy | $32 | +2,005.3% |
| Dec 23, 2025 | Initiated | Oppenheimer | Outperform | $35 | +2,202.6% |
| Dec 12, 2025 | Initiated | William Blair | Outperform | ||
| Dec 03, 2025 | Initiated | Raymond James | Strong Buy | $47 | +2,992.1% |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| RYTM | Rhythm Pharmaceuticals Inc | 7.63B |
| HRMY | Harmony Biosciences Holdings Inc | 1.98B |
| ACAD | Acadia Pharmaceuticals Inc | 3.14B |
| CRBP | Corbus Pharmaceuticals Holdings Inc | 70.27M |
| PTN | Palatin Technologies Inc | 11.70M |
| ALT | Altimmune Inc | 309.28M |
| GPCR | Structure Therapeutics Inc ADR | 1.42B |
| SKYE | Skye Bioscience Inc | 4.78M |
| VKTX | Viking Therapeutics Inc | 3.55B |
| AMLX | Amylyx Pharmaceuticals Inc | 3.94B |
Insider trading
6 filings| Insider | Relationship | Date | Transaction | Cost | Shares | Value | Total held | Form |
|---|---|---|---|---|---|---|---|---|
| Sun Nelson | See Remarks | Sep 11 '26 | Sale | 5.18 | 62,000 | 321,179 | 35,475 | Sep 11 08:14 PM |
| Sun Nelson | See Remarks | Sep 10 '26 | Sale | 5.00 | 14,754 | 73,779 | 97,475 | Sep 11 08:14 PM |
| NELSON SUN | Officer | Sep 11 '26 | Proposed Sale | 5.01 | 33,911 | 169,894 | Sep 11 04:51 PM | |
| NELSON SUN | Officer | Sep 10 '26 | Proposed Sale | 4.92 | 42,843 | 210,788 | Sep 10 05:18 PM | |
| Sun Nelson | Chief Financial Officer | Dec 11 '25 | Buy | 14.40 | 3,000 | 43,200 | 108,484 | Dec 12 08:30 PM |
| Lee Tien-Li | Chief Executive Officer | Dec 11 '25 | Buy | 14.48 | 7,000 | 101,395 | 1,551,613 | Dec 12 08:30 PM |
Held by
AUM| Ticker | Company | AUM |
|---|---|---|
| VTI | Vanguard Morningstar Total Stock Market ETF | AUM: 696.31B |
| VXF | Vanguard Extended Market Index ETF | AUM: 30.79B |
| IBB | iShares Biotechnology ETF | AUM: 11.39B |
| IWC | iShares Micro-Cap ETF | AUM: 1.23B |
| BUSM | EA Bridgeway Ultra-Small Company Market ETF | AUM: 112.81M |
| DXUV | US Vector Equity Portfolio ETF Class Shares | AUM: 671.26M |
| IBBQ | Invesco Nasdaq Biotechnology ETF | AUM: 130.85M |
| DFMC | U.S. Micro Cap Portfolio ETF Class Shares | AUM: 213.58M |
| BIB | ProShares Ultra Nasdaq Biotechnology 2X Shares | AUM: 108.31M |
News
latest 14 of 132- Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension Trials (GlobeNewswire) -64.81%
- Aardvark Therapeutics stock surges as FDA lifts clinical hold (Investing.com) -10.43%
- Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE Data (GlobeNewswire)
- Aardvark Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - AARD (PR Newswire) -6.51%
- Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors (GlobeNewswire) -5.04%
- If You Lost Money Investing in Aardvark Therapeutics, Inc. (AARD) Contact Robbins LLP for Information About Recovering Your Losses (Newsfile)
- Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.31%
- Robbins LLP is Investigating Allegations that Aardvark Therapeutics, Inc. Misled Investors Regarding the Viability and Efficacy of its Lead Drug Candidate ARD-101 (Newsfile) +7.38%
- AARD Stockholders Have Rights - If You Lost Money Investing in Aardvark Therapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses (Business Wire) -6.11%
- Shareholders who lost money in shares of acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) should contact Wolf Haldenstein Immediately (PR Newswire) +5.38%
- Did You Lose Money Investing in Aardvark Therapeutics, Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against AARD (Newsfile)
- Aardvark Therapeutics Inc (AARD) (Q2 2026) Earnings Call Highlights: Board Re-Elected, Auditor ... (GuruFocus.com)
- Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire) -8.62%
- Aardvark Therapeutics (AARD) Scrutinized Again After FDA Hold on Lead Drug Candidate, May Announcement Drives Stock 32% Lower - Hagens Berman (PR Newswire) +6.58%
Quarterly earnings
2026Q2 EPS -0.660 beat -0.874, from -0.660 a year earlier. Sales 0.00 matched 0.00, from 0.00 a year earlier
The outline behind the bar is the estimate. The filled bar is the print. Green beat it, red missed it.
| Period | Reported | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | Surprise | Year-ago quarter | Analysts | Next session |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026Q2ended 2026-06-30 | 2026-08-11 16:30 | -0.660 | -0.874 | -0.660 | 0.00 | 0.00 | EPS -24.5% · sales - | vs 2025Q2, year-ago quarter · EPS 0.0% · sales - | 12 EPS · 8 sales | Open -0.56% vs SPY +0.54%. Close -8.62% vs SPY +0.25% |
| 2026Q1ended 2026-03-31 | 2026-05-07 08:30 | -0.990 | -0.877 | -0.990 | 0.00 | 0.00 | EPS +12.9% · sales - | vs 2025Q1, year-ago quarter · EPS +39.4% · sales - | 12 EPS · 7 sales | Open -2.21% vs SPY +0.17%. Close -4.92% vs SPY -0.31% |
| 2025Q4ended 2025-12-31 | 2026-03-23 16:30 | -0.810 | -0.827 | -0.807 | 0.00 | 0.00 | EPS -2.1% · sales - | vs 2024Q4, year-ago quarter · EPS +224.0% · sales - | 11 EPS · 7 sales | Open -1.60% vs SPY -0.62%. Close -7.26% vs SPY -0.34% |
| 2025Q3ended 2025-09-30 | 2025-11-13 16:30 | -0.750 | -0.799 | -0.750 | 0.00 | 0.00 | EPS -6.1% · sales - | - | 7 EPS · 4 sales | Open -4.60% vs SPY -0.99%. Close -8.66% vs SPY -0.02% |
| 2025Q2ended 2025-06-30 | 2025-08-13 16:30 | -0.660 | -0.600 | -0.662 | 0.00 | 0.00 | EPS +10.0% · sales - | - | 4 EPS · 3 sales | Open -3.57% vs SPY -0.33%. Close +0.54% vs SPY +0.01% |
| 2025Q1ended 2025-03-31 | 2025-05-14 16:30 | -0.710 | -0.673 | -0.429 | 0.00 | 0.00 | EPS +5.5% · sales - | - | 3 EPS · 2 sales | Open +20.71% vs SPY -0.35%. Close +4.00% vs SPY +0.49% |
| 2024Q4ended 2024-12-31 | 2025-03-31 16:30 | -0.250 | -0.410 | -0.405 | 0.00 | 0.00 | EPS -39.0% · sales - | - | 2 EPS · 1 sales | Open -0.13% vs SPY -0.35%. Close +10.39% vs SPY +0.28% |
| 2026Q3ended 2026-09-30 | - | - | -0.725 | - | - | 0.00 | EPS - · sales - | vs 2025Q3, year-ago quarter · EPS - · sales - | 11 EPS · 7 sales | - |
| 2026Q4ended 2026-12-31 | - | - | -0.688 | - | - | 0.00 | EPS - · sales - | vs 2025Q4, year-ago quarter · EPS - · sales - | 11 EPS · 7 sales | - |
| 2027Q1ended 2027-03-31 | - | - | -0.615 | - | - | 0.00 | EPS - · sales - | vs 2026Q1, year-ago quarter · EPS - · sales - | 4 EPS · 3 sales | - |
| 2027Q2ended 2027-06-30 | - | - | -0.583 | - | - | 0.00 | EPS - · sales - | vs 2026Q2, year-ago quarter · EPS - · sales - | 4 EPS · 3 sales | - |
| 2027Q3ended 2027-09-30 | - | - | -0.528 | - | - | 0.00 | EPS - · sales - | vs 2026Q3, year-ago quarter · EPS - · sales - | 4 EPS · 3 sales | - |
| 2027Q4ended 2027-12-31 | - | - | -0.533 | - | - | 0.00 | EPS - · sales - | vs 2026Q4, year-ago quarter · EPS - · sales - | 4 EPS · 3 sales | - |
| 2028Q1ended 2028-03-31 | - | - | -0.726 | - | - | - | EPS - · sales - | vs 2027Q1, year-ago quarter · EPS - · sales - | 1 | - |
| 2028Q2ended 2028-06-30 | - | - | -0.819 | - | - | - | EPS - · sales - | vs 2027Q2, year-ago quarter · EPS - · sales - | 1 | - |
| 2028Q3ended 2028-09-30 | - | - | -0.939 | - | - | - | EPS - · sales - | vs 2027Q3, year-ago quarter · EPS - · sales - | 1 | - |
Annual earnings
2025FY EPS -2.930 beat -2.932, from -5.150 a year earlier. Sales 0.00 matched 0.00, from 0.00 a year earlier
Reported years only. The outline behind the bar is the estimate. A later year with no print stays in the table.
earnings feed, not the snapshot. Not the statement ratio.
| Period | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | P/E, earnings feed |
|---|---|---|---|---|---|---|
| 2030FYestimate | - | 0.240 | - | - | 250.6 | 6.33 |
| 2029FYestimate | - | -1.160 | - | - | 104.38 | - |
| 2028FYestimate | - | -2.211 | - | - | 2.31 | - |
| 2027FYestimate | - | -2.358 | - | - | 0.00 | - |
| 2026FYestimate | - | -3.081 | - | - | 0.00 | - |
| 2025FY | -2.930 | -2.932 | -2.930 | 0.00 | 0.00 | - |
| 2024FY | -5.150 | -2.855 | -0.949 | 0.00 | 0.00 | - |
Quarterly results
2026Q2 revenue 0.00, from 0.00 a year earlier
From the quarterly statement. Not an estimate.
Estimate revisions
Latest snapshot of each period and type. 2026FY E -3.08 per share.
| Period | Type | Scale | Date | Mean | vs prior date |
|---|---|---|---|---|---|
| 2026FY | E | per share | 2026-10-28 | -3.08 | 0.0% |
| 2026Q3 | E | per share | 2026-10-28 | -0.72 | 0.0% |
| 2026FY | R | per share | 2026-10-28 | -3.43 | 0.0% |
| 2026Q3 | R | per share | 2026-10-28 | -0.91 | 0.0% |
| 2026Q4 | E | per share | 2026-10-26 | -0.69 | 0.0% |
| 2026FY | S | per share | 2026-10-25 | 0.00 | - |
| 2026Q3 | S | per share | 2026-10-25 | 0.00 | - |
| 2026Q4 | S | per share | 2026-10-25 | 0.00 | - |
| 2026Q4 | R | per share | 2026-10-23 | -0.84 | -3.4% |
| 2026Q2 | E | per share | 2026-08-12 | -0.82 | -6.4% |
| 2026Q2 | R | per share | 2026-07-29 | -0.94 | 0.0% |
| 2026Q2 | S | per share | 2026-07-17 | 0.00 | - |
| 2026Q1 | E | per share | 2026-04-01 | -0.88 | -1.3% |
| 2026Q1 | R | per share | 2026-04-01 | -0.97 | -5.3% |
| 2026Q1 | S | per share | 2026-03-24 | 0.00 | - |
| 2025FY | E | per share | 2026-03-04 | -2.93 | 0.0% |
| 2025FY | R | per share | 2026-03-04 | -2.96 | 0.0% |
| 2025Q4 | E | per share | 2026-02-27 | -0.83 | -1.0% |
| 2025Q4 | R | per share | 2026-02-27 | -0.87 | -3.9% |
| 2025FY | S | per share | 2026-01-26 | 0.00 | - |
| 2025Q4 | S | per share | 2026-01-26 | 0.00 | - |
| 2025Q3 | E | per share | 2025-11-04 | -0.80 | -0.8% |
| 2025Q3 | R | per share | 2025-11-04 | -0.80 | -4.2% |
| 2025Q3 | S | per share | 2025-11-04 | 0.00 | - |
| 2025Q2 | E | per share | 2025-07-29 | -0.60 | 0.0% |
| 2025Q2 | S | per share | 2025-06-27 | 0.00 | - |
| 2025Q1 | E | per share | 2025-04-01 | -0.67 | +9.8% |
| 2025Q1 | S | per share | 2025-04-01 | 0.00 | - |
Estimate history
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | MRQ |
|---|---|---|---|---|---|---|
| EPS per share | -0.634 | -0.337 | -0.949 | -2.64 | -3.2051 | - |
| Sales USD millions | 0 | 0 | 0 | 0 | 0 | - |
| Shares million shares | 21 | 21 | 22 | 22 | - | 22 |
| Metric | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -2.128 | -0.196 | -0.405 | -0.429 | -0.662 | -0.75 | -0.807 | -0.99 | -0.659 |
| Sales USD millions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shares million shares | 3 | 21 | 22 | 22 | 22 | 22 | 22 | 22 | 22 |
Income statement, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 |
|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 0.04 | 0.04+100.0% | 0.02-80.0% | 0.10-9.1% | 0.11 |
| Gross Profit | -0.04 | -0.04 | -0.02 | -0.10 | -0.11 |
| Selling, General and Administrative Excl. Other | 73.91 | 62.69+175.3% | 22.77+211.1% | 7.32-34.9% | 11.25 |
| Research and Development | 55.02 | 48.90+181.7% | 17.36+287.5% | 4.48-37.5% | 7.17 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -73.95 | -62.73 | -22.79 | -7.42 | -11.36 |
| Interest Expense | 0.00 | 0.00 | 0.00 | - | - |
| Unusual Expense | -0.01 | 0.01-95.5% | 0.22-82.0% | 1.22-47.4% | 2.32 |
| Net Income Before Taxes | -69.89 | -57.59 | -20.59 | -7.21 | -13.56 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -69.89 | -57.59 | -20.59 | -7.21 | -13.56 |
| Net Income From Continuing Operations | -69.89 | -57.59 | -20.59 | -7.21 | -13.56 |
| Net Income | -69.89 | -57.59 | -20.59 | -7.21 | -13.56 |
| EPS (Recurring) per share | -3.20 | -2.64 | -0.94 | -0.30 | -0.56 |
| EPS (Basic, Before Extraordinaries) per share | -3.21 | -2.64 | -0.95 | -0.34 | -0.63 |
| EPS (Diluted) per share | -3.21 | -2.64 | -0.95 | -0.34 | -0.63 |
| EBITDA | -73.91 | -62.69 | -22.77 | -7.32 | -11.25 |
| Non-Operating Income (Expense) | 4.06 | 5.14+113.3% | 2.41+69.7% | 1.42+1083.3% | 0.12 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 7.04 | 3.95+797.7% | 0.44+7.3% | 0.41+32.3% | 0.31 |
| Shares Outstanding million shares | 21.88 | 21.82+0.6% | 21.70+1.5% | 21.380.0% | 21.38 |
| Market Capitalization | 33.26 | 33.26-88.4% | 287.95 | - | - |
Income statement, quarterly
| Metric | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 | 2024Q39/30/2024 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 0.010.0% | 0.010.0% | 0.01 | 0.01-88.9% | 0.01-80.0% | 0.01 | 0.00-100.0% | 0.09+200.0% |
| Gross Profit | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | 0.00 | -0.09 |
| Selling, General and Administrative Excl. Other | 15.07-4.9% | 22.45+114.6% | 18.69+97.8% | 17.69+253.8% | 15.84+162.7% | 10.46+382.0% | 9.45+327.6% | 5.00+195.9% |
| Research and Development | 10.44-20.5% | 16.56+113.7% | 14.29+77.3% | 13.73+238.2% | 13.13+229.9% | 7.75+540.5% | 8.06+423.4% | 4.06+322.9% |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -15.08 | -22.46 | -18.70 | -17.70 | -15.85 | -10.47 | -9.45 | -5.09 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unusual Expense | -0.00-100.0% | 0.010.0% | 0.02-60.0% | -0.04-144.4% | 0.01 | 0.01-90.9% | 0.05 | 0.09-83.0% |
| Net Income Before Taxes | -14.39 | -21.59 | -17.60 | -16.32 | -14.37 | -9.31 | -8.78 | -4.18 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -14.39 | -21.59 | -17.60 | -16.32 | -14.37 | -9.31 | -8.78 | -4.18 |
| Net Income From Continuing Operations | -14.39 | -21.59 | -17.60 | -16.32 | -14.37 | -9.31 | -8.78 | -4.18 |
| Net Income | -14.39 | -21.59 | -17.60 | -16.32 | -14.37 | -9.31 | -8.78 | -4.18 |
| EPS (Recurring) per share | -0.66 | -0.99 | -0.81 | -0.75 | -0.66 | -0.43 | -0.40 | -0.19 |
| EPS (Basic, Before Extraordinaries) per share | -0.66 | -0.99 | -0.81 | -0.75 | -0.66 | -0.43 | -0.40 | -0.20 |
| EPS (Diluted) per share | -0.66 | -0.99 | -0.81 | -0.75 | -0.66 | -0.43 | -0.40 | -0.20 |
| EBITDA | -15.07 | -22.45 | -18.69 | -17.69 | -15.84 | -10.46 | -9.57 | -5.00 |
| Non-Operating Income (Expense) | 0.69-53.7% | 0.89-24.6% | 1.12+55.6% | 1.35+35.0% | 1.49+152.5% | 1.18+1080.0% | 0.72+500.0% | 1.00+614.3% |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 1.95+209.5% | 2.00+769.6% | 1.58+829.4% | 1.50+971.4% | 0.63+1160.0% | 0.23+228.6% | 0.170.0% | 0.14+100.0% |
| Shares Outstanding million shares | 21.88+0.9% | 21.82+0.6% | 21.82+0.6% | 21.75+1.7% | 21.69+747.3% | 21.69+747.3% | 21.70+1.5% | 21.380.0% |
| Market Capitalization | 33.26-88.7% | 82.25-48.8% | 285.77+72.6% | 288.35 | 293.33 | 160.60 | 165.52 | - |
Balance sheet, annual
| Metric | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 |
|---|---|---|---|---|
| Cash & Short Term Investments | 110.03+49.4% | 73.66+637.3% | 9.99-38.0% | 16.11 |
| Short Term Receivables | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 1.86+295.7% | 0.47+23.7% | 0.38-2.6% | 0.39 |
| Total Current Assets | 111.89+50.9% | 74.14+614.9% | 10.37-37.1% | 16.49 |
| Net Property, Plant & Equipment | 0.35-52.1% | 0.73+386.7% | 0.15-40.0% | 0.25 |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 4.94+87.8% | 2.63+26200.0% | 0.010.0% | 0.01 |
| Total Assets | 117.18+51.2% | 77.51+635.4% | 10.54-37.1% | 16.76 |
| Short Term Debt Incl. Current Port. of LT Debt | 0.44+29.4% | 0.34+209.1% | 0.11+10.0% | 0.10 |
| Accounts Payable | 2.07-10.0% | 2.30 | 0.00 | 0.00 |
| Other Current Liabilities | 8.04+251.1% | 2.29+80.3% | 1.27+159.2% | 0.49 |
| Total Current Liabilities | 10.55+114.0% | 4.93+257.2% | 1.38+133.9% | 0.59 |
| Long Term Debt | 0.00-100.0% | 0.44-99.0% | 43.95-0.3% | 44.07 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.00-100.0% | 0.03 | 0.00-100.0% | 0.02 |
| Total Liabilities | 10.55+95.7% | 5.39-88.1% | 45.34+1.5% | 44.68 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00-100.0% | 126.76 | 0.00 | 0.00 |
| Common Equity | 106.63 | -54.64 | -34.80 | -27.92 |
| Total Shareholders Equity | 106.63+47.9% | 72.11 | -34.80 | -27.92 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 106.63+47.9% | 72.11 | -34.80 | -27.92 |
| Total Liabilities & Stockholders Equity | 117.18+51.2% | 77.51+635.4% | 10.54-37.1% | 16.76 |
| Book Value Per Share per share | 4.89 | -2.52 | -1.63 | -1.31 |
| Tangible Book Value Per Share per share | 4.89 | -2.52 | -1.63 | -1.31 |
| Full-Time Employees people | 40+81.8% | 22 | - | - |
| Price to Book Ratio ratio | 0.44 | 2.35 | - | - |
| Return on Assets % | -59.16 | -46.77 | -52.82 | - |
| Return on Equity % | -64.44 | -110.36 | - | - |
| Return on Invested Capital % | -54.01 | -28.38 | -78.76 | -84.02 |
| Quick Ratio ratio | 10.61 | 15.05 | 7.50 | 27.72 |
| Current Ratio ratio | 10.61 | 15.05 | 7.50 | 27.72 |
Cash flow, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 |
|---|---|---|---|---|---|
| Net Income | -69.89 | -57.59 | -20.59 | -7.21 | -13.56 |
| Depreciation | 0.04 | 0.04+100.0% | 0.02 | - | - |
| Other Funds (Non Cash) | 6.63 | 3.03 | -0.28-119.0% | 1.47-66.1% | 4.33 |
| Funds from Operations | -63.22 | -54.53 | -20.85 | -5.74 | -9.23 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -6.19 | 0.36-77.1% | 1.57 | -0.08 | -1.31 |
| Cash from Operating Activities | -69.41 | -54.17 | -19.28 | -5.82 | -10.54 |
| Capital Expenditures | -0.00 | -0.10 | -0.11 | 0.00 | 0.00 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 116.55 | -49.57 | -11.89 | 0.00 | 0.00 |
| Purchase of Investments | -4.95 | -129.60 | -11.89 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 121.50 | 80.03 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | 116.55 | -49.67 | -12.00 | 0.00 | 0.00 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 0.71 | 89.25+7.3% | 83.18 | 0.00-100.0% | 0.23 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 0.71 | 89.25+7.3% | 83.18 | 0.00-100.0% | 0.23 |
| Proceedsfrom Stock Options | 0.45 | 88.88+7.3% | 82.85 | 0.00 | 0.00 |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00 | 0.00 | 0.00 | -1.00 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | -1.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | -1.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 0.71 | 89.25+7.3% | 83.18 | 0.00 | -0.78 |
| Net Change in Cash | 47.85 | -14.59-128.1% | 51.91 | -5.82 | -11.32 |
| Free Cash Flow | -69.41 | -54.27 | -19.39 | -5.82 | -10.54 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Taxes & Investment Tax Credit | - | 0.00 | 0.00 | 0.00 | 0.00 |
Balance sheet, quarterly
| Metric | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 | 2024Q39/30/2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 73.87-47.9% | 91.20-39.7% | 110.03+49.4% | 126.35+53.4% | 141.82 | 151.26 | 73.66+637.3% | 82.36 |
| Short Term Receivables | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 6.79+130.2% | 2.38-27.7% | 1.86+295.7% | 2.86+822.6% | 2.95 | 3.29 | 0.47+23.7% | 0.31 |
| Total Current Assets | 80.66-44.3% | 93.58-39.5% | 111.89+50.9% | 129.21+56.3% | 144.77 | 154.55 | 74.14+614.9% | 82.67 |
| Net Property, Plant & Equipment | 0.63+21.2% | 0.27-57.1% | 0.35-52.1% | 0.44-47.6% | 0.52 | 0.63 | 0.73+386.7% | 0.84 |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 0.17-92.2% | 4.74+157.6% | 4.94+87.8% | 3.58+1456.5% | 2.19 | 1.84 | 2.63+26200.0% | 0.23 |
| Total Assets | 81.46-44.8% | 98.59-37.2% | 117.18+51.2% | 133.23+59.1% | 147.47 | 157.03 | 77.51+635.4% | 83.74 |
| Short Term Debt Incl. Current Port. of LT Debt | 0.40-4.8% | 0.34-12.8% | 0.44+29.4% | 0.43+34.4% | 0.42 | 0.39 | 0.34+209.1% | 0.32 |
| Accounts Payable | 2.09-58.7% | 4.49+75.4% | 2.07-10.0% | 4.44+562.7% | 5.06 | 2.56 | 2.30 | 0.67 |
| Other Current Liabilities | 3.90-19.4% | 6.78+123.8% | 8.04+251.1% | 5.86+261.7% | 4.84 | 3.03 | 2.29+80.3% | 1.62 |
| Total Current Liabilities | 6.39-38.0% | 11.60+94.0% | 10.55+114.0% | 10.74+311.5% | 10.31 | 5.98 | 4.93+257.2% | 2.61 |
| Long Term Debt | 0.28+21.7% | 0.00-100.0% | 0.00-100.0% | 0.12-78.2% | 0.23 | 0.34 | 0.44-99.0% | 0.55 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.00-100.0% | 0.00-100.0% | 0.00-100.0% | 0.00 | 0.01 | 0.02 | 0.03 | 0.00 |
| Total Liabilities | 6.66-36.9% | 11.60+83.0% | 10.55+95.7% | 10.85+243.4% | 10.55 | 6.34 | 5.39-88.1% | 3.16 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00-100.0% | 0.00-100.0% | 0.00 | 0.00 | 126.76 | 126.76 |
| Common Equity | 74.80-45.4% | 86.99-42.3% | 106.63 | 122.38 | 136.93 | 150.69 | -54.64 | -46.17 |
| Total Shareholders Equity | 74.80-45.4% | 86.99-42.3% | 106.63+47.9% | 122.38+51.9% | 136.93 | 150.69 | 72.11 | 80.58 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 74.80-45.4% | 86.99-42.3% | 106.63+47.9% | 122.38+51.9% | 136.93 | 150.69 | 72.11 | 80.58 |
| Total Liabilities & Stockholders Equity | 81.46-44.8% | 98.59-37.2% | 117.18+51.2% | 133.23+59.1% | 147.47 | 157.03 | 77.51+635.4% | 83.74 |
| Book Value Per Share per share | 3.42-45.8% | 3.99-42.6% | 4.89 | 5.63 | 6.31 | 6.95 | -2.52 | -2.16 |
| Tangible Book Value Per Share per share | 3.42-45.8% | 3.99-42.6% | 4.89 | 5.63 | 6.31 | 6.95 | -2.52 | -2.16 |
| Full-Time Employees people | 55 | - | 40+81.8% | 72 | - | 54 | 22 | - |
| Price to Book Ratio ratio | 0.44 | 0.77 | 2.33 | 2.11 | 1.95 | -2.98 | -3.58 | - |
| Return on Assets % | -61.06 | -54.67 | -59.16 | -44.96 | - | - | -46.77 | - |
| Return on Equity % | -66.02 | -58.79 | -64.44 | -48.06 | - | - | -110.36 | - |
| Return on Invested Capital % | -19.16 | -24.82 | -16.50 | -13.32 | -10.48 | -6.16 | -12.10 | -5.15 |
| Quick Ratio ratio | 12.63 | 8.06 | 10.61 | 12.03 | 14.04 | 25.86 | 15.05 | 31.65 |
| Current Ratio ratio | 12.63 | 8.06 | 10.61 | 12.03 | 14.04 | 25.86 | 15.05 | 31.65 |
Cash flow, quarterly
| Metric | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 | 2024Q3 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -14.39 | -21.59 | -17.60 | -16.32 | -14.37 | -9.31 | -8.78 | - |
| Depreciation | 0.010.0% | 0.010.0% | 0.01 | 0.01 | 0.01 | 0.01 | -0.12 | - |
| Other Funds (Non Cash) | 2.02+1453.8% | 1.99+637.0% | 3.84 | -1.21 | 0.13 | 0.27-10.0% | -0.82-415.4% | - |
| Funds from Operations | -12.36 | -19.59 | -13.75 | -17.52 | -14.23 | -9.03 | -9.72 | - |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Changes in Working Capital | -5.24-219.6% | 0.72 | -0.67-182.7% | -1.00 | 4.38 | -2.36 | 0.81+17.4% | - |
| Cash from Operating Activities | -17.60 | -18.87 | -14.42 | -18.52 | -9.84 | -11.39 | -8.90 | - |
| Capital Expenditures | 0.00 | 0.00 | 0.00 | -0.00 | -0.09 | 0.00 | -0.01 | - |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Purchase or Sale of Investments | 28.75+202.6% | 34.25 | 24.30 | 29.25 | 9.50 | -112.62 | -11.89 | - |
| Purchase of Investments | 0.00 | 0.00 | -4.95 | 0.00 | 0.00 | -124.65 | -11.89 | - |
| Sale Or Maturity of Investments | 28.75+202.6% | 34.25+184.7% | 29.25 | 29.25 | 9.50 | 12.03 | 0.00 | - |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Cash from Investing Activities | 28.75+205.5% | 34.25 | 24.30 | 29.25 | 9.41 | -112.62 | -11.89 | - |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Preferred Dividends (Cash Flow) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Change in Capital Stock | 0.26 | 0.00-100.0% | -2.11-1418.7% | 2.56 | -0.07 | 88.88 | 0.16 | - |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Sale of Common Pref Stock | 0.26 | 0.00-100.0% | -2.11-1418.7% | 2.56 | -0.07 | 88.88 | 0.16 | - |
| Proceedsfrom Stock Options | 0.26 | 0.00-100.0% | -2.19 | 2.39 | -0.08 | 88.77 | 0.00 | - |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Cash from Financing Activities | 0.26 | 0.00-100.0% | -2.11-1418.7% | 2.56 | -0.07 | 88.88 | 0.16 | - |
| Net Change in Cash | 11.41 | 15.38 | 7.77 | 13.29 | -0.51 | -35.14 | -20.64 | - |
| Free Cash Flow | -17.60 | -18.87 | -14.42 | -18.52 | -9.94 | -11.39 | -8.91 | - |
Revenue breakdown
| Revenue split | - |
|---|
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 8.10% | 1.0M | 12.8M | 584.55K |
| 2026-10-15 | 4.32% | 0.6M | 12.8M | 133.93K |
| 2026-09-30 | 3.70% | 0.5M | 12.8M | 216.28K |
| 2026-09-15 | 3.31% | 0.4M | 12.8M | 254.14K |
| 2026-08-31 | 4.00% | 0.5M | 12.7M | 249.06K |
| 2026-08-14 | 4.80% | 0.6M | 12.7M | 266.33K |
| 2026-07-31 | 5.13% | 0.7M | 12.7M | 268.15K |
| 2026-07-15 | 5.13% | 0.7M | 12.7M | 269.50K |
| 2026-06-30 | 4.20% | 0.5M | 12.6M | 195.08K |
| 2026-06-15 | 7.27% | 0.9M | 12.6M | 192.88K |
| 2026-05-29 | 7.87% | 1.0M | 12.6M | 300.00K |
| 2026-05-15 | 8.08% | 1.0M | 12.6M | 289.97K |
| 2026-04-30 | 10.46% | 1.3M | 12.1M | 282.50K |
| 2026-04-15 | 9.55% | 1.2M | 12.1M | 291.00K |
| 2026-03-31 | 9.40% | 1.1M | 12.1M | 288.39K |
| 2026-03-13 | 11.50% | 1.4M | 12.0M | 278.00K |
| 2026-02-27 | 15.02% | 1.8M | 12.0M | 191.93K |
| 2026-02-13 | 15.62% | 1.9M | 12.0M | 199.42K |
| 2026-01-30 | 14.20% | 1.8M | 12.5M | 201.38K |
| 2026-01-15 | 12.99% | 1.6M | 12.5M | 202.40K |
Option chain
expiry 2026-11-20| Type | Strike | Bid | Ask | Last | IV | Open int | Volume | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|
| call | 2.50 | 0.00 | 4.90 | 0.06 | 0.000 | 233 | 0.00 | 0.000 | 0.000 | 0.000 |
| call | 5.00 | 0.00 | 4.30 | 0.01 | 0.000 | 235 | 0.00 | 0.000 | 0.000 | 0.000 |
| call | 7.50 | 0.00 | 4.90 | 0.65 | 0.000 | 259 | 0.00 | 0.000 | 0.000 | 0.000 |
| call | 10.00 | 0.00 | 1.55 | 0.90 | 7.494 | 2.00 | 0.00 | 0.159 | -0.026 | 0.001 |
| call | 12.50 | 0.00 | 4.90 | 0.50 | 112.39 | 77.00 | 0.00 | 1.000 | 0.000 | 0.000 |
| call | 15.00 | 0.00 | 4.90 | 0.00 | 111.28 | 0.00 | 0.00 | 1.000 | 0.000 | 0.000 |
| put | 2.50 | 0.00 | 4.90 | 1.20 | 0.000 | 43.00 | 0.00 | 0.000 | 0.000 | 0.000 |
| put | 5.00 | 1.05 | 5.90 | 3.75 | 0.000 | 96.00 | 0.00 | 0.000 | 0.000 | 0.000 |
| put | 7.50 | 3.50 | 8.40 | 2.60 | 0.000 | 240 | 0.00 | 0.000 | 0.000 | 0.000 |
| put | 10.00 | 6.00 | 10.90 | 4.80 | 0.000 | 0.00 | 0.00 | -0.105 | -0.062 | 0.000 |
| put | 12.50 | 8.50 | 13.40 | 6.66 | 0.000 | 0.00 | 0.00 | -0.107 | -0.064 | 0.000 |
| put | 15.00 | 11.00 | 16.00 | 0.00 | 0.000 | 0.00 | 0.00 | -0.108 | -0.065 | 0.000 |
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-11-10 | 4 | Statement of changes in beneficial ownership of securities | 2026-11-06 | SEC |
| 2026-11-10 | 4 | Statement of changes in beneficial ownership of securities | 2026-11-06 | SEC |
| 2026-11-10 | 4 | Statement of changes in beneficial ownership of securities | 2026-11-06 | SEC |
| 2026-10-23 | 8-K | Current report | 2026-10-23 | SEC |
| 2026-10-22 | 8-K | Current report | 2026-10-22 | SEC |
| 2026-10-08 | 4 | Statement of changes in beneficial ownership of securities | 2026-10-07 | SEC |
| 2026-10-08 | 3 | Initial statement of beneficial ownership of securities | 2026-10-07 | SEC |
| 2026-10-08 | 8-K | Current report | 2026-10-06 | SEC |
| 2026-09-11 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-09-11 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-10 | SEC |
| 2026-09-10 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-08-21 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-14 | SEC |
| 2026-08-21 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-14 | SEC |
| 2026-08-21 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-14 | SEC |
| 2026-08-21 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-14 | SEC |
| 2026-08-17 | 8-K | Current report | 2026-08-14 | SEC |
| 2026-08-11 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-06-30 | SEC |
| 2026-08-11 | 8-K | Current report | 2026-08-11 | SEC |
| 2026-07-10 | ARS | Annual report to security holders. | 2025-12-31 | SEC |
| 2026-07-10 | DEF 14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | 2026-08-14 | SEC |
| 2026-06-29 | PRE 14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | 2026-08-14 | SEC |
| 2026-06-12 | 8-K | Current report | 2026-06-10 | SEC |
| 2026-05-14 | 8-K | Current report | 2026-05-14 | SEC |
| 2026-05-07 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-03-31 | SEC |
| 2026-05-07 | 8-K | Current report | 2026-05-07 | SEC |
| 2026-04-03 | EFFECT | Effectiveness filing by commission order | SEC | |
| 2026-04-03 | 424B5 | SEC | ||
| 2026-03-30 | CORRESP | SEC | ||
| 2026-03-25 | UPLOAD | Upload Submission | SEC | |
| 2026-03-24 | 8-K | Current report | 2026-03-23 | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 0 | 0 | 394.96K | 2 |
| 2026-08 | 0 | 0 | 0 | 0 |
| 2026-07 | 0 | 0 | 0 | 0 |
| 2026-06 | 0 | 0 | 0 | 0 |
| 2026-05 | 0 | 0 | 0 | 0 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 0 | 0 | 0 | 0 |
| 2026-02 | 0 | 0 | 0 | 0 |
| 2026-01 | 0 | 0 | 0 | 0 |
| 2025-12 | 144.60K | 2 | 0 | 0 |
| 2025-11 | 0 | 0 | 0 | 0 |
Institutional holders
| Manager | % owned |
|---|---|
| Decheng Capital LLC | 17.96% |
| CITADEL ADVISORS LLC | 5.88% |
| Laurion Capital Management LP | 4.73% |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.58% |
| AQR CAPITAL MANAGEMENT LLC | 2.20% |
| EcoR1 Capital, LLC | 1.82% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.38% |
| CANTOR FITZGERALD, L. P. | 1.07% |
| BlackRock, Inc. | 0.86% |
| GEODE CAPITAL MANAGEMENT, LLC | 0.64% |
Funds
| Fund | % owned |
|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND | 1.87% |
| VANGUARD EXTENDED MARKET INDEX FUND | 0.64% |
| Fidelity Small Cap Index Fund | 0.58% |
| iShares Biotechnology ETF | 0.41% |
| Fidelity Extended Market Index Fund | 0.31% |
| VANGUARD RUSSELL 2000 INDEX FUND | 0.30% |
| iShares Micro-Cap ETF | 0.20% |
| Schwab Small-Cap Index Fund | 0.13% |
| Ultra-Small Company Market Fund | 0.11% |
| Fidelity Total Market Index Fund | 0.10% |
OakChart. AARD. Cached 15 minutes. Terms